Percheron Therapeutics (ASX:PER) has announced the completion of a nine-month toxicology study in non-human primates for its lead program, avicursen. …
Percheron Therapeutics updates on Avicursen primate toxicology study
September 30, 2024 Australian Biotech
Latest Video
New Stories
-
Pharmac announces expanded access to three cancer medicines
October 11, 2024 - - Latest News -
Novartis-led partnership says heart health shouldn't be dependent on where you live
October 11, 2024 - - Latest News -
Bondi Junction response must include increased funding and support for severe mental illness
October 11, 2024 - - Latest News -
New report unveils hidden cost of Alzheimer’s disease, with cases to double by 2050
October 10, 2024 - - Latest News -
Amplia Therapeutics CEO shares Prime Minister's Prize for Innovation
October 10, 2024 - - Latest News -
Healthy Bones Australia calls for greater Government commitment to bone health
October 9, 2024 - - Latest News -
TGA approves new indication for Telix’s Illuccix to include patient selection for PSMA-targeted therapy
October 9, 2024 - - Australian Biotech